Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on May 2, 2016, covering events occurring on April 27, 2016, and April 29, 2016. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the amendment of an executive employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate events rather than financial performance data.
Material Changes and Corporate Actions
- Board Appointment: Effective April 27, 2016, Myron Kaplan was appointed as a director to serve until the 2017 annual meeting. This appointment was made at the request of Manchester Securities Corp. (Manchester), exercising its right to appoint a second board member under a March 3, 2015, letter agreement.
- Compensation for Appointment: Mr. Kaplan was granted an option to purchase 50,000 shares of common stock as compensation for joining the Board.
- Executive Employment Amendment: Effective April 29, 2016, the employment agreement with Randy Milby, Chief Scientific Officer, was amended. Mr. Milby is now an at-will employee following the expiration of his previous agreement on April 30, 2016. This change coincides with the company's ongoing search for a new Chief Executive Officer.
Background on Financing and Shareholder Rights
The filing details a backstop financing agreement entered into on March 3, 2015, with Manchester. Key terms include:
- Loan Facility: Manchester agreed to lend up to $4,500,000 (capped at $3,000,000) less proceeds from warrant exercises prior to April 30, 2015. The company did not access this loan because warrant exercise proceeds exceeded the threshold required to trigger the facility.
- Warrants Issued: In consideration for the backstop, the company issued Manchester a warrant for 200,000 shares at $7.00 per share (5-year term) and extended the expiration of an existing warrant for 390,720 shares at $3.4375 per share to March 24, 2016.
- Board Rights: Manchester retains the right to appoint up to two board members or observers as long as it holds company securities.
Outlook and Risks
The filing notes that the company is currently conducting a search for a new Chief Executive Officer. No specific financial guidance or forward-looking projections were provided in this document.
Key Facts for Investor Verification
- Verify the status of the search for a new Chief Executive Officer and the implications of Randy Milby's transition to at-will employment.
- Confirm the total number of shares outstanding and the dilution impact of the warrants held by Manchester Securities Corp. (200,000 new shares + 390,720 extended shares).
- Review the March 3, 2015, letter agreement to understand the full scope of Manchester's rights and any potential future financing obligations.
- Check subsequent filings for the appointment of a new CEO and any updates to the company's liquidity position.